Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update
© The Author(s). 2017
Received: 1 March 2017
Accepted: 21 April 2017
Published: 28 April 2017
Liver Imaging Reporting and Data System (LI-RADS) is a system for interpreting and reporting of imaging features on multidetector computed tomography (MDCT) and magnetic resonance (MR) studies in patients at risk for hepatocellular carcinoma (HCC). American College of Radiology (ACR) sustained the spread of LI-RADS to homogenizing the interpreting and reporting data of HCC patients. Diagnosis of HCC is due to the presence of major imaging features. Major features are imaging data used to categorize LI-RADS-3, LI-RADS-4, and LI-RADS-5 and include arterial-phase hyperenhancement, tumor diameter, washout appearance, capsule appearance and threshold growth. Ancillary are features that can be used to modify the LI-RADS classification. Ancillary features supporting malignancy (diffusion restriction, moderate T2 hyperintensity, T1 hypointensity on hapatospecifc phase) can be used to upgrade category by one or more categories, but not beyond LI-RADS-4. Our purpose is reporting an overview and update of major and ancillary MR imaging features in assessment of HCC.
KeywordsHCC LI-RADS Magnetic resonance imaging
Hepatocellular carcinoma (HCC) is one of the most common human solid malignancies worldwide [1, 2]. The most important risk factor for the development of HCC is liver cirrhosis, regardless of its etiology . Among patients with cirrhosis, those with chronic viral infection (hepatitis B and C) and high alcohol intake have the highest risks of HCC development. Imaging surveillance is a widely accepted tool that increases the likelihood of early detection of HCC and an accurate detection and characterization of focal liver nodule on patient at risk for HCC is mandatory since the management of HCC patients differs to other malignant or benign nodules . According to National Comprehensive Cancer Network (NCCN)  and the guidelines of European Association for the Study of the Liver (EASL) and American Association for the Study Liver Diseases (AASLD), diagnostic criteria, to characterize HCC, can only be applied to cirrhotic patients and should be based on the detection of the typical hallmark of HCC (hypervascular in the arterial phase with washout in the portal venous or delayed phases) . However, the current imaging-based criteria have several limitations, including the lack of established consensus regarding the exact definitions of imaging features, binary categorization (either definite or not definite HCC), and failure to address non-HCC malignancies and vascular invasion . Therefore American College of Radiology (ACR) sustained the spread of Liver Imaging Reporting and Data System (LI-RADS) to homogenizing the interpreting, reporting and data collection of HCC imaging . LI-RADS is a scheme for interpreting and reporting of imaging features on multidetector computed tomography (CT) and magnetic resonance (MR) studies in patients at risk for hepatocellular carcinoma (HCC) [5–7]. In the current (v. 2014) LI-RADS , the diagnosis of HCC is based on the presence of major imaging features. These are features used to categorize LI-RADS- category 3 (LR-3), LI-RADS- category 4 (LR-4), and LI-RADS- category 5 (LR-5) and include arterial-phase hyperenhancement, tumor diameter, washout appearance, capsule appearance, and threshold growth . Ancillary features are imaging features that can be used to change the LI-RADS category . Ancillary features favoring malignancy (diffusion restriction, moderate T2 hyperintensity, T1 hypointensity on hepatospecific phase) can upgrade category, but not beyond LR-4. In contrast, ancillary features favoring benignity can decrease category [5, 6].
As required in most clinical trials, MDCT presents the key imaging modality in the patient assessment. This is due to its wide availability, standardization, and ability to scan the whole abdomen and chest in one setting. MRI plays a role in HCC assessment of patients with contraindication to iodine contrast medium . However, considering the evidences on the accuracy of the various imaging modalities on HCC assessment , so as the guidelines of the European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Working Group , MRI is the technique to choose in pre-treatment setting. It is a valuable diagnostic tool providing lesion morphological and functional data, thanks to hepatospecific contrast medium and DW sequences [11–14].
To standardize imaging technique among institutions, LI-RADS outlines technical requirements for MRI. Precontrast, arterial phase, portal venous phase, and delayed phase are all required for MRI with extracellular agents. Each phase contributes to characterization of LI-RADS major features. For MRI with hepatobiliary agents, a delay of 15–20 min for gadoxetic acid and a delay of 1 h for gadobenate dimeglumine consistently provide high-quality hepatobiliary phase imaging. In the setting of cirrhosis increasing the delay for hepatobiliary phase imaging to 30 min or more for gadoxetic acid and 2–3 h for gadobenate dimeglumine may improve parenchymal enhancement somewhat . Although the delayed phase cannot be used to evaluate washout appearance, it can be used to evaluate capsule appearance, a major feature of HCC. Also, the delayed phase and hepatobiliary phase can be used to evaluate hypointensity on both sequences; these are ancillary features favoring malignancy and so can be used to upgrade the category. Late arterial phase is strongly preferred over early arterial phase, as HCC enhancement usually is greater in the late than in the early phase, and some HCCs show hyperenhancement only in the late arterial phase . Unenhanced T1-weighted (T1-W) out of phase (OP)/in phase (IP) is required. T1-W OP/IP allows identification of fat and iron and is necessary for assessment of some ancillary features. T2-W sequences are required, improving distinction between solid and nonsolid lesions and are necessary for assessment of some ancillary LI-RADS features. DWI is suggested but not required .
Our purpose is reporting an overview and update of major and ancillary MR imaging features in assessment of HCC.
This overview and update is the result of autonomous studies without protocol and registration number.
Several electronic dataset were searched: PubMed (US National Library of Medicine, http://www.ncbi.nlm.nih.gov/pubmed), Scopus (Elsevier, http://www.scopus.com/), Web of Science (Thomson Reuters, http://apps.webofknowledge.com/) and Google Scholar (https://scholar.google.it/). The following search criteria have been used: “hepatocellular carcinoma” AND “diffusion magnetic resonance imaging” AND “characterization, “hepatocellular carcinoma” AND “dynamic contrast enhanced magnetic resonance imaging” AND “characterization, “hepatocellular carcinoma” AND “EOB-GD-DTPA contrast medium” AND “characterization, “hepatocellular carcinoma” AND “multimodal imaging” AND “characterization”. The search covered the years from January 2000 to January 2017. Moreover, the reference lists of the found papers were analysed for papers not indexed in the electronic databases.
All titles and abstracts were analysed and exclusively the studies reporting MRI, EOB-GD-DTPA MRI, DWI results in the characterization of HCC were retained.
The inclusion criteria were: clinical study evaluating MR assessment of HCC, clinical study evaluating functional MR imaging criteria in the assessment of patients with HCC, and clinical study evaluating DWI and EOB-GD-DTPA to assessing HCC patient. Articles published in the English language from January 2000 to January 2017 were included. Exclusion criteria were unavailability of full text, general overview articles and congress abstracts; studies with lesion higher than 20 mm. There was not define a minimum number of patients as an inclusion criteria.
Early diagnosis is a critical step in the management of HCC patients. The identification of the specific vascular profile characterized by contrast arterial uptake followed by washout in the venous phases has allowed defining the non-invasive diagnostic criteria for HCC according to AASLD and EASL-EORTC guidelines [4, 5]. The typical hallmark has 100% specificity when demonstrated on dynamic contrast study, both on CT than on MRI, in patients at high risk of HCC . However, arterial hyperehnancement and wash out appearance have a sensitivity rate of 50–60% in lesion smaller than 2 cm and thus a biopsy is still needed . The typical vascular profile is correlated to hemodynamic changes in nodule during hepatocarcinogenesis, and to understand the hemodynamics of HCC is important for the accurate diagnostic analysis, because there is an intense correlation between their hemodynamics and pathophysiology . Angiogenesis such as sinusoidal capillarization and unpaired arteries shows gradual increase during carcinogenesis from high-grade dysplastic nodule to classic hypervascular HCC. In accordance with this angiogenesis, the intranodular portal supply is decreased, whereas the intranodular arterial supply is first decreased during the early stage and then increased in parallel with increasing grade of malignancy of the lesion. On the other hand, the main drainage vessels of hepatocellular nodules change from hepatic veins to hepatic sinusoids and then to portal veins, mainly due to disappearance of the hepatic veins from the nodules . The nodule appearance on arterial phase relative, considering the intra-lesion arterial supply, can be categorized into four types. Type I when the nodule is isodense to the surrounding cirrhotic liver parenchyma, and it is due to the same intranodular arterial blood supply relative to the surrounding liver. Type II, when the nodule is hypodense to the surrounding cirrhotic liver parenchyma, indicating decreased arterial blood supply. Type III a part of the nodule demonstrating hyperdensity due a partially increased arterial supply and type IV entirely hyperdense indicating entirely increased arterial supply [16, 17]. These findings reveal the significant correlation or strong tendency between type I and low grade dysplastic nodule and early HCC, type II and high grade dysplastic nodule and early HCC, type III and well differentiated HCC and type IV and moderately or poorly differentiated HCC [16, 17]. Also in early HCC, there is not perinodular enhancement on portal or equilibrium phase of contrast study, but it is definite in hypervascular classical HCC.
During hepatocarcinogenesis multi-step changes of drainage vessels and peritumoral enhancement occurred. In dysplastic nodules or early HCCs, the main drainage route from the tumor is intranodular or perinodular hepatic vein. However, because hepatic veins disappear from the tumor during very early stage of hepatocarcinogenesis, drainage vessels change to hepatic sinusoids. This drainage was well visualized in the late phase of contrast studies. Histological examination revealed continuity between a tumor sinusoid and a portal venule in the pseudocapsule (encapsulated HCC) or surrounding hepatic sinusoids (HCC without pseudocapsule). In moderately differentiated HCC with pseudocapsule formation, the communication between tumor sinusoids and the surrounding hepatic sinusoids are also blocked, and then, the portal venules in the pseudo-capsule finally become the main drainage vessel from the tumor. In accordance with the changes of the drainage vessels, thin to thick corona enhancement appears surrounding the tumor. Corona enhancement is thicker in encapsulated HCC and thin in HCC without pseudocapsule .
Arterial phase hyperenhancement
Arterial phase hyperenhancement is an essential prerequisite for definitely HCC (LR-5), but it is non-specific. In fact considering the hepatocarcinogenesis this feature may be not present, so as it may be observed in benign entities such as dysplastic nodules and arterio-portal shunts [1, 2]. Holland et al. showed, in proven HCC patients, that the majority (93%) of hypervascular lesions on arterial phase that were not detected on T2-W and portal and/or equilibrium phase of contrast study were non-neoplastic . Conversely, Kim et coworkers  demonstrated that the most significant findings associated with HCC, in nodules smaller than 20 mm, were arterial phase hypernhancement. Ehman et al. demonstrated that arterial hypenhancement was the most commonly observed major criterion on 159 (86%) of 184 proven HCC, and was seen slightly more frequently at CT vs. MRI (87 vs. 86%, p = 1.00). Between the two readers, there was agreement on arterial phase characteristics in 156 (95%) cases (κ = 0.75) . Conversely Burrel et al.  showed that sensitivity of MR was superior to CT to detect HCC (58/76 [76%] versus 43/70 [61%], respectively). Sensitivity of MR for detection of additional nodules decreased with size (>20 mm: 6/6 [100%]; 10–20 mm: 16/19 [84%]; <10 mm: 7/22 [32%]) and was superior to CT for nodules 10 to 20 mm (84 vs. 47%). Non specific hypervascular nodules >5 mm at MR were HCC in two thirds of the cases . Special attention must be given to perfusion alterations, common condition in cirrhotic livers that may be false positive. These are areas of arterial hyperenhancement most frequently caused by arterioportal shunts [22, 23]. These alterations are usually peripheral, wedge shaped, and isointense relative to the surrounding parenchyma on T1- and T2-W MR images, and can be confidently characterized as LR-1. Perfusion alterations can also be nodular and it is difficult to distinguish from a true lesion [18, 23]. Areas of nodular arterial hyperenhancement seen exclusively during the arterial phase are more appropriately categorized as LR-2 [13, 18], but if corresponding others observations (eg, hyperintensity T2 signal or restricted diffusion) should be categorized as either LR-3 or LR-4 depending on its size and nonvascular features. Some areas of perfusion alteration can occur secondary to focal liver lesions, including HCC .
Capsule appearance is defined as a peripheral rim of smooth hyperenhancement in the portal or delayed phase (Fig. 3). The rim of enhancement is not always a true tumor capsule, but may represent a pseudocapsule corresponding to fibrous tissue and dilated sinusoids around a nodule [16, 17, 28]. Anis and coworkers showed as the capsule appearance has a high positive predictive value for HCC in at-risk patients . Dioguardi Burgio et al.  showed as hyperintense capsule was present either on portal phase in 11/46 and in 24/25 HCCs imaged with gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, respectively (24 vs. 96%). A hypointense capsule appearance was present on hepatobiliary phase in 8/46 and 0/22 HCCs evaluated with gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, respectively (17 vs. 0%) . Conversely to Dioguardi Burgio et al. that analyzed two different contrast media, Zhang et al.  compared diagnostic accuracy of CT and MRI to predicting of malignancy and showed that CT against MR produced false-negative findings of pseudo-capsule by 42.9% with an underestimated LI-RADS score by 16.9% for LR- 3, 37.3% for LR- 4, and 8.5% for LR- 5. CT produced significantly lower accuracy (54.3 versus 67.8%) and sensitivity (31.6 versus 71.1%) than MRI in the prediction of malignancy . Also Corwin et al.  compared the diagnostic accuracy of CT respected to MR to grading LI-RADS. The most important finding of this study was that nearly half (42%) of observations were significantly upgraded on MRI compared with CT, and approximately one third of upgrades were to category 4, 5, or 5 V. The most common reason for the upgrade by MRI was the visualization of arterial hyperenhancement or a delayed enhancing capsule not seen on CT . It is clear that these features should be correctly identified since they are major features on LI-RADS.
Hypointense signal on hepatobiliary phase
Other ancillary features (intalesional fat, corona enhancement, mosaic architecture and iron sparing in iron overloaded)
MR imaging diagnosis of HCC is based mainly on assessment of vascularity, capsule appearance, and signal intensity in the hepatobiliary phase. MR imaging also permit assessment of ancillary imaging features, that can be divided into those that favor the diagnosis of HCC specifically (intralesional fat, corona enhancement, nodule-in-nodule architecture, and mosaic architecture) and those that favor the diagnosis of malignancy but are not specific for HCC (mild-moderate T2 hyperintensity, restricted diffusion, and lesional iron sparing) [5–7, 81].
Intralesional fat is the presence of lipid within a nodule in higher concentration than in the hepatic parenchyma . This feature can be detected at MR by observing signal loss on out-of-phase compared with in-phase T1-weighted GRE images. In a patient at risk for HCC, the detection of intralesional fat in a solid nodule raises concern for malignancy or premalignancy. In fact, this feature does not establish the diagnosis of HCC, however, as the differential diagnosis includes high-grade dysplastic nodule and occasionally low-grade dysplastic nodule .
Corona enhancement is a feature of hypervascular, progressed HCC and refers to enhancement of the venous drainage area in the peritumoral parenchyma . It is as a rim (“corona”) of enhancement around a progressed, hypervascular HCC in the late arterial phase or early portal venous phase, with fading to isoenhancement at subsequent phases. This feature begins a few seconds after tumor enhancement, so that corona and tumor enhancement may appear to overlap. This overlap may cause the tumor to appear larger than it really is. Its presence helps to differentiate small hypervascular HCCs from pseudolesions, however it is not a feature of early HCC [16, 82].
Mosaic architecture refers to the presence within a mass of randomly distributed internal nodules differing in enhancement, intensity, often separated by fibrous septa. This feature is characteristic of large HCCs and reflects the mosaic configuration observed at pathologic evaluation. It is unusual in tumors other than HCC .
Lesional iron sparing refers to relative paucity of iron in a solid mass compared with that of background iron-overloaded liver. This feature raises concern for premalignancy or malignancy because high-grade dysplastic nodules and HCCs characteristically are iron “resistant”. However it is not specific for high-grade dysplastic nodule or HCC, but other non-HCC malignancies may have this appearance .
Early diagnosis is a critical step in the management of HCC patients. The identification of the specific vascular profile characterized by contrast arterial uptake followed by washout in the venous phases has 100% specificity when demonstrated on dynamic contrast study, in patients at high risk of HCC. Although the arterial phase hyperenhancement is an essential prerequisite for definitely HCC, it is not sufficient for LR-5 categorization. Hypointensity on hepatospecific phase and wash-out appearance are the most relevant diagnostic sign for differentiating low-risk from high-risk nodules in patients at risk for HCC. Therefore the use of EOB-GD-DTPA should be considered in this category of patients. The capsule appearance, T2-W hyperintensity and restricted diffusion have a high positive predictive value for HCC and may be associated to other imaging features for LIRADS characterization.
The authors are grateful to Alessandra Trocino, librarian at the National Cancer Institute of Naples, Italy. Moreover, for the collaboration, authors are grateful to Maria Bruno, Laura Galeani, Rita Guarino, Leandro Eto and Assunta Zazzaro.
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analysed during the current study.
VG conceived of the study, and participated in its design, coordination and drafting of the manuscript. RF participated in the studies collection and drafted the manuscript. AA, OC, FF, ML, RP, FI, AP participated in the studies collection. All authors read and approved the final manuscript.
The authors have no conflict of interest to be disclosed. The authors confirm that the article is not under consideration for publication elsewhere. Each author has participated sufficiently to take public responsibility for the manuscript content.
Consent for publication
Ethics approval and consent to participate
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology. 2011;53:1020–2.View ArticlePubMedPubMed CentralGoogle Scholar
- Izzo F, Albino V, Palaia R, et al. Hepatocellular carcinoma: preclinical data on a dual-lumen catheter kit for fibrin sealant infusion following loco-regional treatments. Infect Agent Cancer. 2014;9(1):39.View ArticlePubMedPubMed CentralGoogle Scholar
- NCCN Clinical Practice Guidelines in Oncology on hepatobiliary cancer. Version 2016. http://www.nccn.org.
- European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48(5):599–641. doi:https://doi.org/10.1016/j.ejca.2011.12.021. Erratum in: Eur J Cancer. 2012 May; 48(8): 1255–6.View ArticleGoogle Scholar
- An C, Rakhmonova G, Choi JY, et al. Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm. Clin Mol Hepatol. 2016;22(2):296–307.View ArticlePubMedPubMed CentralGoogle Scholar
- American College of Radiology. Liver Imaging Reporting and Data System Version 2014. ACR Web site < http://www.acr.org/Quality-Safety/Resources/LIRADS >. Accessed 15 Apr 2016.
- Santillan CS, Tang A, Cruite I, et al. Understanding LI-RADS: a primer for practical use. Magn Reson Imaging Clin N Am. 2014;22:337–52.View ArticlePubMedGoogle Scholar
- Schima W, Ba-Ssalamah A, Kurtaran A, et al. Post-treatment imaging of liver tumours. Cancer Imaging. 2007;7(Spec No A):S28–36.View ArticlePubMedPubMed CentralGoogle Scholar
- Granata V, Petrillo M, Fusco R, et al. Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan-Experience of High Volume Oncologic Institute. Gastroenterol Res Pract. 2013;2013:469097.View ArticlePubMedPubMed CentralGoogle Scholar
- Neri E, Bali MA, Ba-Ssalamah A, et al. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol. 2016;26:921–31.View ArticlePubMedGoogle Scholar
- Granata V, de Lutio di Castelguidone E, Fusco R, et al. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area. Radiol Med. 2016;121(2):122–31.View ArticlePubMedGoogle Scholar
- Prince MR, Zhang H, Zou Z, et al. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol. 2011;196(2):W138–43. Google Scholar
- Izzo F, Palaia R, Albino V, et al. S. Hepatocellular carcinoma and liver metastases: clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments. Infect Agent Cancer. 2015;10:11.View ArticlePubMedPubMed CentralGoogle Scholar
- Granata V, Fusco R, Catalano O, et al. Percutaneous ablation therapy of hepatocellular carcinoma with irreversible electroporation: MRI findings. AJR Am J Roentgenol. 2015;204(5):1000–7.View ArticlePubMedGoogle Scholar
- Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97–104.View ArticlePubMedGoogle Scholar
- Matsui O, Kobayashi S, Sanada J, et al. Hepatocelluar nodules in liver cirrhosis: hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging. 2011;36(3):264–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Park YN, Kim MJ. Hepatocarcinogenesis: imaging-pathologic correlation. Abdom Imaging. 2011;36:232–43.View ArticlePubMedGoogle Scholar
- Holland AE, Hecht EM, Hahn WY, et al. Importance of small (< or = 20-mm) enhancing lesions seen only during the hepatic arterial phase at MR imaging of the cirrhotic liver: evaluation and comparison with whole explanted liver. Radiology. 2005;237(3):938–44.View ArticlePubMedGoogle Scholar
- Kim TK, Lee KH, Jang HJ, et al. K. Analysis of gadobenate dimeglumine-enhanced MR findings for characterizing small (1-2-cm) hepatic nodules in patients at high risk for hepatocellular carcinoma. Radiology. 2011;259(3):730–8.View ArticlePubMedGoogle Scholar
- Ehman EC, Behr SC, Umetsu SE, et al. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas. Abdom Radiol (NY). 2016;41(5):963–9.View ArticlePubMed CentralGoogle Scholar
- Burrel M, Llovet JM, Ayuso C, et al. Barcelona Clínic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to live transplantation: an explant correlation. Hepatology. 2003;38(4):1034–42.View ArticlePubMedGoogle Scholar
- Brancatelli G, Baron RL, Peterson MS, et al. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. AJR Am J Roentgenol. 2003;180(4):1007–14.View ArticlePubMedGoogle Scholar
- Yu JS, Kim KW, Jeong MG, et al. Non- tumorous hepatic arterial-portal venous shunts: MR imaging findings. Radiology. 2000;217(3):750–6.View ArticlePubMedGoogle Scholar
- Colagrande S, Centi N, Galdiero R, et al. Transient hepatic intensity differences. 1. Those associated with focal lesions. AJR Am J Roentgenol. 2007;188(1):154–9.View ArticlePubMedGoogle Scholar
- Sharma P, Kalb B, Kitajima HD, et al. Optimization of single injection liver arterial phase gadolinium enhanced MRI using bolus track real-time imaging. J Magn Reson Imaging. 2011;33(1):110–8.View ArticlePubMedGoogle Scholar
- Hecht EM, Holland AE, Israel GM, et al. Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis. Radiology. 2006;239(2):438–47.View ArticlePubMedGoogle Scholar
- Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247(2):311–30.View ArticlePubMedGoogle Scholar
- Efremidis SC, Hytiroglou P. The multistep process of hepatocarcinogenesis in cirrhosis with imaging correlation. Eur Radiol. 2002;12:753–64.View ArticlePubMedGoogle Scholar
- Jang HJ, Kim TK, Burns PN, Wilson SR. Enhancement patterns of hepatocellular carcinoma at contrast-enhanced US: comparison with histologic differentiation. Radiology. 2007;244(3):898–906.View ArticlePubMedGoogle Scholar
- Marrero JA, Hussain HK, Nghiem HV, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl. 2005;11(3):281–9.View ArticlePubMedGoogle Scholar
- Choi MH, Choi JI, Lee YJ, et al. MRI of Small Hepatocellular Carcinoma: Typical Features Are Less Frequent Below a Size Cutoff of 1.5 cm. AJR Am J Roentgenol. 2016;27:1–8.Google Scholar
- Granito A, Galassi M, Piscaglia F, et al. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther. 2013;37(3):355–63.View ArticlePubMedGoogle Scholar
- Becker AS, Barth BK, Marquez PH, et al. Increased interreader agreement in diagnosis of hepatocellular carcinoma using an adapted LI-RADS algorithm. Eur J Radiol. 2017;86:33–40.View ArticlePubMedGoogle Scholar
- Fowler KJ, Brown JJ, Narra VR. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis. Hepatology. 2011;54(6):2227–37.View ArticlePubMedGoogle Scholar
- Anis M. Imaging of hepatocellular carcinoma: new approaches to diagnosis. Clin Liver Dis. 2015;19(2):325–40.View ArticlePubMedGoogle Scholar
- Dioguardi Burgio M, Picone D, Cabibbo G, et al. MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine. Abdom Radiol (NY). 2016;41(8):1546–54.View ArticleGoogle Scholar
- Zhang YD, Zhu FP, Xu X, et al. Liver Imaging Reporting and Data System: Substantial Discordance Between CT and MR for Imaging Classification of Hepatic Nodules. Acad Radiol. 2016;23(3):344–52.View ArticlePubMedGoogle Scholar
- Corwin MT, Fananapazir G, Jin M, et al. Differences in Liver Imaging and Reporting Data System Categorization Between MRI and CT. AJR Am J Roentgenol. 2016;206(2):307–12.View ArticlePubMedGoogle Scholar
- Granata V, Cascella M, Fusco R, et al. Immediate adverse reactions to gadolinium-based MR contrast media: a retrospective analysis on 10,608 examinations. Biomed Res Int. 2016;2016:3918292.PubMedPubMed CentralGoogle Scholar
- Hope TA, Fowler KJ, Sirlin CB, et al. Hepatobiliary agents and their role in LI-RADS. Abdom Imaging. 2015;40(3):613e25.View ArticleGoogle Scholar
- Ahn SS, Kim MJ, Lim JS, et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010;255(2):459e66.View ArticleGoogle Scholar
- Davenport MS, Viglianti BL, Al-Hawary MM, et al. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology. 2013;266(2):452e61.View ArticleGoogle Scholar
- Kim SY, Park SH, Wu EH, et al. Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses. AJR Am J Roentgenol. 2015;204(6):1220e7.Google Scholar
- Tsuda N, Harada K, Matsui O. Effect of change in transporter expression on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging during hepatocarcinogenesis in rats. J Gastroenterol Hepatol. 2011;26(3):568e76.View ArticleGoogle Scholar
- Kim T, Murakami T, Hasuike Y, et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOB-DTPA. J Magn Reson Imaging. 1997;7(4):683e8.View ArticleGoogle Scholar
- Nassif A, Jia J, Keiser M, et al. Visualization of hepatic uptake transporter function in healthy subjects by using gadoxetic acid-enhanced MR imaging. Radiology. 2012;264(3):741e50.View ArticleGoogle Scholar
- Kim H, Kim MJ, Park MS, et al. Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging. J Comput Assist Tomogr. 2010;34(1):113e20.View ArticleGoogle Scholar
- Chernyak V, Kim J, Rozenblit AM, et al. Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors. J Magn Reson Imaging. 2011;34(2):301e9.View ArticleGoogle Scholar
- Esterson YB, Flusberg M, Oh S, et al. Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors. Clin Radiol. 2015;70(7):723e9.View ArticleGoogle Scholar
- Tong HF, Liang HB, Mo ZK, et al. Quantitative analysis of gadoxetic acid-enhanced magnetic resonance imaging predicts histological grade of hepatocellular carcinoma. Clin Imaging. 2017;43:9–14.View ArticlePubMedGoogle Scholar
- Jeon I, Cho ES, Kim JH, et al. Feasibility of 10-Minute Delayed Hepatocyte Phase Imaging Using a 30° Flip Angle in Gd-EOB-DTPA-Enhanced Liver MRI for the Detection of Hepatocellular Carcinoma in Patients with Chronic Hepatitis or Cirrhosis. PLoS One. 2016;11(12):e0167701.View ArticlePubMedPubMed CentralGoogle Scholar
- Toyoda H, Kumada T, Tada T, et al. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC. Hepatol Int. 2015;9(1):84–92.View ArticlePubMedGoogle Scholar
- Golfieri R, Garzillo G, Ascanio S, Renzulli M. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines. Dig Dis. 2014;32(6):696–704.View ArticlePubMedGoogle Scholar
- Ahn SS, Kim MJ, Lim JS, et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010;255:459–66.View ArticlePubMedGoogle Scholar
- Golfieri R, Renzulli M, Lucidi V, et al. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2 cm) HCC in cirrhosis. Eur Radiol. 2011;21(6):1233–42.View ArticlePubMedGoogle Scholar
- Golfieri R, Grazioli L, Orlando E, et al. Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging. 2012;36(3):648–57.View ArticlePubMedGoogle Scholar
- Tsuda N, Kato N, Murayama C, et al. Potential for differential diagnosis with gadolinium- ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in experimental hepatic tumors. Invest Radiol. 2004;39:80–8.View ArticlePubMedGoogle Scholar
- Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology. 2005;234:468–78.View ArticlePubMedGoogle Scholar
- Saito K, Kotake F, Ito N, et al. Gd- EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4:1–9.View ArticlePubMedGoogle Scholar
- Lee SA, Lee CH, Jung WY, et al. Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB- DTPA enhanced MRI: initial experience. Magn Reson Imaging. 2011;29:83–90.View ArticlePubMedGoogle Scholar
- Kudo M. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma? Oncology. 2010;78 Suppl 1:87–93.View ArticlePubMedGoogle Scholar
- Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202–10.View ArticlePubMedGoogle Scholar
- Ouedraogo W, Tran-Van Nhieu J, et al. Evaluation of noninvasive diagnostic criteria for hepatocellular carcinoma on pretransplant MRI (2010): correlation between MR imaging features and histological features on liver specimen]. J Radiol. 2011;92(7–8):688–700.View ArticlePubMedGoogle Scholar
- Sofue K, Burke LM, Nilmini V, et al. Liver imaging reporting and data system category 4 observations in MRI: Risk factors predicting upgrade to category 5. J Magn Reson Imaging. 2017. doi:https://doi.org/10.1002/jmri.25627.PubMedGoogle Scholar
- Hwang J, Kim YK, Jeong WK, et al. Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease: Diffusion-weighted Imaging for Characterization. Radiology. 2015;276(1):137–46.View ArticlePubMedGoogle Scholar
- Kim JE, Kim SH, Lee SJ, Rhim H. Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. AJR Am J Roentgenol. 2011;196(6):W758–65.View ArticlePubMedGoogle Scholar
- Hussain HK, Syed I, Nghiem HV, et al. T2- weighted MR imaging in the assessment of cirrhotic liver. Radiology. 2004;230:637–44.View ArticlePubMedGoogle Scholar
- Kim YK, Lee YH, Kim CS, Han YM. Added diagnostic value of T2-weighted MR imaging to gadolinium-enhanced three-dimensional dynamic MR imaging for the detection of small hepatocel- lular carcinomas. Eur J Radiol. 2008;67:304–10.View ArticlePubMedGoogle Scholar
- Brancatelli G, Federle MP, Blachar A, Grazioli L. Hemangioma in the cirrhotic liver: diagnosis and natural history. Radiology. 2001;219:69–74.View ArticlePubMedGoogle Scholar
- Shankar S, Kalra N, Bhatia A, et al. Role of Diffusion Weighted Imaging (DWI) for Hepatocellular Carcinoma (HCC) Detection and its Grading on 3 T MRI: A Prospective Study. J Clin Exp Hepatol. 2016;6(4):303–10.View ArticlePubMedGoogle Scholar
- Xu PJ, Yan FH, Wang JH, et al. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr. 2010;34(4):506–12.View ArticlePubMedGoogle Scholar
- Lee MH, Kim SH, Park MJ, et al. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol. 2011;197(5):W868–75.View ArticlePubMedGoogle Scholar
- Piana G, Trinquart L, Meskine N, et al. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol. 2011;55:126–32.View ArticlePubMedGoogle Scholar
- Granata V, Fusco R, Catalano O, et al. Intravoxel incoherent motion (IVIM) in diffusion-weighted imaging (DWI) for Hepatocellular carcinoma: correlation with histologic grade. Oncotarget. 2016;7(48):79357–64.PubMedPubMed CentralGoogle Scholar
- Nakanishi M, Chuma M, Hige S, et al. Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma. Ann Surg Oncol. 2012;19(4):1302–9.View ArticlePubMedGoogle Scholar
- Nasu K, Kuroki Y, Tsukamoto T, et al. Diffusion-weighted imaging of surgically resected hepatocellular carcinoma: imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade. AJR Am J Roentgenol. 2009;193:438–44.View ArticlePubMedGoogle Scholar
- Sutherland T, Watts J, Ryan M, et al. Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: Direct comparison with ultrasound screening. J Med Imaging Radiat Oncol. 2017;61(1):34–9.View ArticlePubMedGoogle Scholar
- Koh D, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;188:1622–35.View ArticlePubMedGoogle Scholar
- Scialpi M, Palumbo B, Pierotti L, et al. Detection and characterization of focal liver lesions by split-bolus multidetector-row CT: diagnostic accuracy and radiation dose in oncologic patients. Anticancer Res. 2014;34(8):4335–44.PubMedGoogle Scholar
- Sforza V, Martinelli E, Ciardiello F, et al. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol. 2016;22(28):6345–61.View ArticlePubMedPubMed CentralGoogle Scholar
- Granata V, Fusco R, Avallone A, Filice F, Tatangelo F, Piccirillo M, Grassi R, Izzo F, Petrillo A. Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows. Oncotarget. 2017. doi:https://doi.org/10.18632/oncotarget.17227.
- Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014;273(1):30–50.View ArticlePubMedPubMed CentralGoogle Scholar